A pre-existing inflamed tumor microenvironment characterized by active IFNγ signaling and activated T cells was previously described to predict for clinical response to anti-PD-1/PD-L1 therapies in various tumor types [18,19,33]. This evidence concerns the gene CD274 and neoplasm.